SG3 Management’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-19,000
Closed -$3.2M 1234
2021
Q4
$4.83M Sell
19,000
-33,500
-64% -$9.79M 0.1% 179
2021
Q3
$20.2M Buy
52,500
+13,600
+35% +$5.02M 0.61% 21
2021
Q2
$9.14M Buy
+38,900
New +$6.95M 0.32% 60
2020
Q3
Sell
-24,000
Closed -$1.67M 999
2020
Q2
$1.54M Buy
+24,000
New +$1.31M 0.11% 224

Other funds holding MRNA

SG3 Management's MRNA Position: Q1 2022 in Review

SG3 Management sold out of Moderna (MRNA) in Q1 2022, closing a stake of 19,000 shares — an estimated $3.2M sold.

SG3 Management first reported a position in MRNA in Q2 2020 and held it in 4 quarters. The position peaked at $20.2M in Q3 2021. 1,007 funds tracked by Wall St. Rank hold MRNA as of Q1 2022.

  • SG3 Management reported no remaining Moderna position as of Q1 2022 after selling out during the quarter.
  • SG3 Management sold 19,000 Moderna shares in Q1 2022, an estimated $3.2M.
  • SG3 Management first reported a position in Moderna in Q2 2020 and held it in 4 quarters.
  • SG3 Management's Moderna position peaked at $20.2M in Q3 2021.
  • 1,007 funds tracked by Wall St. Rank held Moderna as of Q1 2022.

Based on SG3 Management's 13F filing for Q1 2022, filed 16 May 2022.